Gemcitabine + Cisplatin + Nab-paclitaxel + Cemiplimab for Biliary Tract Cancer

(GAP Cemi Trial)

This trial tests a new treatment combination to determine if it can shrink tumors in patients with biliary tract cancer, potentially making them eligible for surgery. Participants will receive a combination of chemotherapy drugs and cemiplimab, an experimental drug. The trial seeks individuals diagnosed with biliary tract cancer that cannot currently be surgically removed but has not spread to distant parts of the body. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should not have had prior systemic therapy or be on certain immunosuppressive medications. It's best to discuss your specific medications with the trial team.

Research has shown that cemiplimab, the treatment under study, has generally been well-tolerated in previous trials. Patients reported that its safety remains stable over time. Although some experienced serious side effects, such as immune-related liver issues, these were rare. Specifically, liver inflammation occurred in 2.4% of patients, with very few severe cases. Overall, cemiplimab's safety profile suggests it is manageable for most patients, especially when combined with chemotherapy, as in this study.¹²³⁴⁵

Researchers are excited about cemiplimab for biliary tract cancer because it represents a new approach by harnessing the power of the immune system. Unlike traditional chemotherapy options like gemcitabine and cisplatin, cemiplimab is an immunotherapy drug that targets and blocks a specific protein called PD-1 on immune cells, potentially enhancing the body's natural ability to fight cancer. This unique mechanism of action could offer improved outcomes for patients, providing hope for a more effective treatment option alongside existing chemotherapy regimens.

Research has shown that cemiplimab, when combined with chemotherapy, can effectively treat biliary tract cancer. In one study, 88% of patients who received cemiplimab at the recommended dose experienced significant tumor shrinkage. In this trial, all participants will receive cemiplimab along with chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel). This combination treatment also extends patient survival and delays disease progression compared to chemotherapy alone. These findings suggest that cemiplimab, together with gemcitabine, cisplatin, and nab-paclitaxel, could be promising for treating challenging cases of biliary tract cancer.⁶⁷⁸⁹¹⁰